Eventide Asset Management’s Pacira BioSciences PCRX Stock Holding History

Eventide Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-13,300	Closed	-$1.18M	–	115
2015 Q1	$1.18M	Hold	13,300	–	–	0.09%	103
2014 Q4	$1.18M	Hold	13,300	–	–	0.13%	94
2014 Q3	$1.29M	Hold	13,300	–	–	0.18%	85
2014 Q2	$1.22M	Hold	13,300	–	–	0.17%	94
2014 Q1	$931K	Hold	13,300	–	–	0.14%	92
2013 Q4	$765K	Buy	+13,300	New	+$699K	0.24%	66

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Eventide Asset Management's PCRX Position: Q2 2015 in Review

Eventide Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2015, closing a stake of 13,300 shares — an estimated $1.18M sold.

Eventide Asset Management first reported a position in PCRX in Q4 2013 and held it in 6 quarters. The position peaked at $1.29M in Q3 2014. 187 funds tracked by Wall St. Rank hold PCRX as of Q2 2015.

Eventide Asset Management reported no remaining Pacira BioSciences position as of Q2 2015 after selling out during the quarter.
Eventide Asset Management sold 13,300 Pacira BioSciences shares in Q2 2015, an estimated $1.18M.
Eventide Asset Management first reported a position in Pacira BioSciences in Q4 2013 and held it in 6 quarters.
Eventide Asset Management's Pacira BioSciences position peaked at $1.29M in Q3 2014.
187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2015.

Based on Eventide Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.